# Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

> **NCT04342962** · PHASE2 · TERMINATED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 25 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** tagraxofusp

## Key facts

- **NCT ID:** NCT04342962
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-16
- **Primary completion:** 2024-01-18
- **Final completion:** 2024-01-18
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** poor enrollment
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04342962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04342962, "Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04342962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*